Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a vaccine stop head and neck cancer from coming back?

NCT ID NCT03821272

Disease control Sponsor: University of Arkansas Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a vaccine called PepCan in 17 people who had head and neck cancer and were in remission. The goal was to see if the vaccine is safe and can reduce the chance of the cancer returning. Participants received seven injections of either PepCan or a placebo over about two years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PepCan (HPV 16 E6 peptides combined with Candin)
What this could lead to
If it works, this could point toward a way to lower the chance of head and neck cancer coming back after remission.
What could go wrong
This is a very small early-phase trial with only 17 participants, so results may not apply to everyone. The vaccine may not reduce recurrence or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

17 people

The number who actually took part.

Started

Nov 2019

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Able to provide informed consent 2. Male or female 18 years of age or older 3. Squamous cell carcinoma of the head and neck who have completed curative therapy (surgery and/or radiation and/or chemotherapy) therapy within the previous 120 days 4. Performance status of Eastern Cooperative Oncology Group (ECOG) 0-2 5. No Evidence of Disease (NED) based on clinical and/or radiographic evaluations 6. Vital Signs recorded 1. Blood pressure (≤160/95 mm Hg acceptable) 2. Heart rate (50-100 beats per min acceptable) 3. Respiratory rate (≥ 12 ≤25 breaths per min acceptable) 4. Temperature (≤100°F acceptable) 7. Blood work done at Screening Visit 1. White count (≥3x109/L acceptable) 2. Hemoglobin (≥ 7 g/dL acceptable) 8. Willing and able to comply with the requirements of the protocol Exclusion Criteria: 1. Positive urine pregnancy test for women of childbearing potential 2. Being pregnant or attempting to be pregnant within the period of study participation 3. Women who are breast feeding or plan to breast feed within the period of study participation 4. Patients who are allergic to Candin® or yeast 5. History of severe asthma requiring emergency room visit or hospitalization within the past 5 years 6. Patients who have previously received PepCan 7. History of recurrence of squamous cell carcinoma of the head and neck 8. If in the opinion of the Principal Investigator or other Investigators, it is not in the best interest of the patient to enter or continue in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck cancer

Contacts and locations

Locations

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas, 72205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.